Tecentriq

CAS: 1380723-44-3

Pharmacological action and mechanism

Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells

and may contribute to the inhibition of anti-tumor immune responses in tumor

microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1

receptors and antigen presentation showed that the cells inhibited the activity of

cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a

monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1

and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune

responses, including activation of anti-tumor immune responses, does not induce

antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition

of pd-l1 activity leads to reduced tumor growth.

We can customize according to customer’s requirement

if you have any question pls mail us or call us